The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Long-Term Treatment of Osteopetrosis with Recombinant Human Interferon Gamma
Abstract
BACKGROUND: Congenital osteopetrosis is a rare osteosclerotic bone disease characterized by both a defect in osteoclastic function and reduced generation of superoxide by leukocytes. The disease is frequently fatal during the first decade of life. A six-month trial of therapy with recombinant human interferon gamma-1b in eight patients with osteopetrosis provided evidence of benefit, prompting this study of more prolonged therapy. METHODS: We studied 14 patients with severe osteopetrosis treated with subcutaneous injections of recombinant human interferon gamma-1b (1.5 micrograms per kilogram of body weight per dose) three times per week for at least 6 months; 11 patients were treated for 18 months. We assessed the effect of therapy by evaluating the patients' clinical status, measuring blood counts and biochemical markers of bone turnover, and performing bone marrow imaging and bone biopsies. RESULTS: After 6 months of therapy, all 14 patients had decreases in trabecular-bone area (determined by histomorphometric analysis of bone-biopsy specimens) and increases in bone marrow space (determined by marrow imaging), and the improvement was sustained in the 11 patients treated for 18 months. The mean (+SD) hemoglobin concentration increased from 7.5 +/- 2.9 to 10.5 +/- 0.3 g per deciliter (P = 0.05), and superoxide generation by granulocyte-macrophage colonies increased (P < 0.001) after 18 months of therapy. In six patients for whom pretreatment data were available, there was a 96 percent decrease in the frequency of infections requiring antibiotic therapy during interferon treatment. There were no side effects necessitating the discontinuation of therapy. CONCLUSIONS: Long-term therapy with interferon gamma in patients with osteopetrosis increases bone resorption and hematopoiesis and improves leukocyte function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garrett, I. R., Boyce, B. F., Oreffo, R. O., Bonewald, L., Poser, J., & Mundy, G. R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114485 · Cited by 806
Hanson, D. A., Weis, M. A. E., Bollen, A.-M., Maslan, S. L., Singer, F. R., & Dr. Eyre, D. R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650071119 · Cited by 656
Gowen, M., & Mundy, G. R. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2478 · Cited by 476
Ezekowitz, R. A. B., Dinauer, M. C., Jaffe, H. S., Orkin, S. H., & Newburger, P. E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807213190305 · Cited by 262
Treatment of Congenital Osteopetrosis with High-Dose Calcitriol
Key, L., Carnes, D., Cole, S., Holtrop, M., Bar-Shavit, Z., Shapiro, F., Arceci, R., Steinberg, J., Gundberg, C., Kahn, A., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402163100701 · Cited by 172
Self-citationPreferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma
Gowen, M., Nedwin, G. E., & Mundy, G. R. (1986) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650010511 · Cited by 151
Superoxide and bone resorption
Key, L. L., Wolf, W. C. D., Gundberg, C. M., & Ries, W. L. (1994) · Bone · doi:10.1016/8756-3282(94)90821-4 · Cited by 130
Self-citationKey, L. L., Ries, W. L., Taylor, R., Hays, B. D., & Pitzer, B. (1990) · Bone · doi:10.1016/8756-3282(90)90058-7 · Cited by 115
Self-citationRecombinant human interferon gamma therapy for osteopetrosis
Key, L. L., Ries, W. L., Rodriguiz, R. M., & Hatcher, H. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82557-0 · Cited by 114
Self-citationMann, G. N., Jacobs, T. W., Buchinsky, F. J., Armstrong, E. C., Li, M., Ke, H. Z., Ma, Y., Jee, W. S. S., & Epstein, S. (1994) · Endocrinology · doi:10.1210/endo.135.3.8070349 · Cited by 86
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990
Osteoimmunology: Interactions of the Bone and Immune System
Lorenzo, J., Horowitz, M., & Choi, Y. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0038 · Cited by 563
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Metadata
- Authors
- Key, L. L., Rodriguiz, R. M., Willi, S. M., Wright, N. M., Hatcher, H. C., Eyre, D. R., Cure, J. K., Griffin, P. P., & Ries, W. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-06-15
- Volume
- 332
- Issue
- 24
- Pages
- 1594-1599
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2322534530
- Cited by
- 278
- References
- 15
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Treatment of Osteopetrosis with Recombinant Human Interferon Gamma. https://app.cochat.ai/papers/10.1056/nejm199506153322402
- The paper
- Key, L. L., Rodriguiz, R. M., Willi, S. M., Wright, N. M., Hatcher, H. C., Eyre, D. R., Cure, J. K., Griffin, P. P., & Ries, W. L. (1995). Long-Term Treatment of Osteopetrosis with Recombinant Human Interferon Gamma. New England Journal of Medicine. https://doi.org/10.1056/nejm199506153322402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.